Unfortunately, CTNNB1 is not directly targetable with current therapies and often represents a negative prognostic factor for tumor aggressiveness (5), whereas BRAF targeting can be more promising, as suggested by the recent data presented at ASCO 2021 (6). This evidence concerns the gene BRAF and neoplasm.